Skip to main content
main-content

Latest news stories

Latest news stories

08-11-2019 | Non-small-cell lung cancer | News

Ensartinib could expand treatment options for ALK-positive NSCLC

At least half of patients with crizotinib-resistant ALK translocation-positive non-small-cell lung cancer respond to treatment with the new-generation ALK inhibitor ensartinib, including those with brain metastases, phase II study data show.

07-11-2019 | Prostate cancer | News

Detection bias may contribute to reduced prostate cancer risk in diabetes

The reduced prostate cancer risk seen in men with diabetes may be partly explained by detection bias due to a lower biopsy rate following an elevated prostate-specific antigen test result, population-based study data show.

06-11-2019 | Castration-sensitive prostate cancer | Highlight | News

Different ADT combination therapies offer similar prostate cancer survival benefits

Adding docetaxel, abiraterone acetate, enzalutamide, or apalutamide to androgen deprivation therapy  significantly improves survival for men with metastatic hormone-sensitive prostate cancer, with little difference between each drug, a network meta-analysis shows.

04-11-2019 | Prostate cancer | News

Factors mediating statin prostate cancer protective effect identified

Statin use is associated with a reduced risk for low- and high-Gleason score prostate cancer, but the association is modified by the duration, dose, and type of statin, study results suggest.

01-11-2019 | Non-small-cell lung cancer | News

Further data support lorlatinib as an option in advanced ROS1-positive NSCLC

The early potential of lorlatinib for the treatment of patients with advanced ROS1-positive non-small-cell lung cancer who are either tyrosine kinase inhibitor-naïve or have previously received crizotinib has been re-emphasized in the expanded analysis of a phase I–II trial.

31-10-2019 | Non-small-cell lung cancer | News

TP53/ATM co-mutation associated with NSCLC checkpoint blockade response

In immune checkpoint inhibitor-treated patients with non-small-cell lung cancer, co-mutation in TP53 and ATM is associated with a higher tumor mutational burden and better overall survival versus one or no mutations, according to a multi-cohort study.

30-10-2019 | Prostate cancer | News

Durable efficacy of androgen suppression plus radiotherapy for prostate cancer salvage confirmed

A one-off post-hoc analysis of the GETUG-AFU 16 study has confirmed the long-term benefit of adding short-term androgen suppression to radiotherapy for salvage treatment in patients with increasing prostate-specific antigen concentration after radical prostatectomy.

29-10-2019 | Recurrence | News

Reassurance for TNF inhibitor use in RA patients with history of cancer

Tumor necrosis factor inhibitors are not associated with an increased risk for new or recurrent cancer in patients with rheumatoid arthritis and prior malignancy, confirms a meta-analysis.

28-10-2019 | Non-small-cell lung cancer | Highlight | News

Network meta-analysis identifies best clinical choices for EGFR-mutated NSCLC

Osimertinib and gefitinib plus pemetrexed-based chemotherapy offer the best survival outcomes for patients with advanced EGFR-mutated non-small-cell lung cancer compared with other first-line treatments, shows a network meta-analysis of randomized trials.

25-10-2019 | Risk factors | News

Interleukin inhibitors linked to elevated cancer risk

Results of a meta-analysis suggest that treatment with interleukin inhibitors may be associated with an increased risk for cancer and infection among people with rheumatic diseases.

24-10-2019 | Prostate cancer | News

Association between 5α-reductase inhibitors, prostate cancer mortality replicated

An analysis of the SEER–Medicare database has confirmed the link between use of 5α-reductase inhibitors, primarily for benign prostatic enlargement, and increased risk for prostate cancer-specific and all-cause mortality.

23-10-2019 | Mesothelioma | Highlight | News

STELLAR shows potential of tumor treating fields in mesothelioma

Combining tumor treating fields with standard chemotherapy could be a promising option for the first-line treatment of inoperable malignant pleural mesothelioma, say the STELLAR investigators.

22-10-2019 | Renal cell carcinoma | ESMO 2019 | News

Benefit of nivolumab–tivozanib, nivolumab beyond progression shown in metastatic RCC

Studies presented at the ESMO 2019 Congress propose that patients with metastatic renal cell carcinoma may benefit from a combination of nivolumab and the VEGFR tyrosine kinase inhibitor tivozanib, or by continuing with single-agent nivolumab past initial disease progression.

22-10-2019 | Screening | News

Life-gained selection approach could expand benefits of lung cancer screening

Using a life–years gained approach to select patients for lung cancer screening could maximize its benefits for current and ex-smokers who have both a high risk for lung cancer and a long life expectancy, US research suggests.

21-10-2019 | Lung cancer | News

BCG vaccination linked to reduced incidence of lung cancer

Receipt of the Bacillus Calmette-Guérin vaccine may reduce the risk for developing lung cancer, suggests a secondary analysis of a clinical trial conducted in American–Indian and Alaska Native populations.

21-10-2019 | Renal cell carcinoma | ESMO 2019 | News

Treatment-free survival proposed as novel RCC immunotherapy endpoint

Time spent off treatment could be used as a novel clinical trial endpoint for patients undergoing renal cell carcinoma immunotherapy, suggest study findings reported at the ESMO Congress 2019 in Barcelona, Spain.

18-10-2019 | Renal cell carcinoma | ESMO 2019 | News

KEYNOTE-427 updates confirm pembrolizumab benefit for advanced RCC

The latest findings from the KEYNOTE-427 trial add to the efficacy evidence for first-line pembrolizumab against advanced or metastatic renal cell carcinoma regardless of histology.

18-10-2019 | Non-small-cell lung cancer | News

Electronic nose predicts PD-1 inhibitor response

An electronic nose can predict if patients with advanced non-small-cell lung cancer will respond to immune checkpoint inhibitor therapy by analyzing the composition of volatile organic compounds in patients’ exhaled breath, say researchers.

17-10-2019 | Renal cell carcinoma | ESMO 2019 | News

Neoadjuvant nivolumab tested for metastatic RCC

Results from the ADAPTeR study suggest that giving nivolumab before and after cytoreductive nephrectomy or metastatic biopsy may be a feasible strategy for patients with treatment-naïve metastatic clear cell renal cell carcinoma.

17-10-2019 | Non-small-cell lung cancer | News

Durvalumab NSCLC clinical benefit achieved without negative impact on PROs

Analysis of data from the PACIFIC trial shows that levels of key patient-reported outcomes such as cough, fatigue, and quality of life, do not differ significantly between patients with advanced non-small-cell lung cancer treated with durvalumab after chemoradiotherapy and those who received placebo.

Image Credits